Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an In Vitro Infection Model

Antimicrob Agents Chemother. 2017 Nov 22;61(12):e01052-17. doi: 10.1128/AAC.01052-17. Print 2017 Dec.

Abstract

We previously demonstrated that for tazobactam administered in combination with ceftolozane, the pharmacokinetic-pharmacodynamic (PK-PD) index that best described tazobactam efficacy was the percentage of the dosing interval that tazobactam concentrations were above a threshold (%T>threshold). Using data from studies of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs), a relationship between tazobactam %T>threshold and reduction in log10 CFU/ml from baseline, for which the tazobactam threshold concentration was the product of the isolate's ceftolozane-tazobactam MIC value and 0.5, was identified. However, since the kinetics of cephalosporin hydrolysis vary among ESBLs and compounds, it is likely that the translational relationship used to derive the tazobactam threshold concentration varies among enzymes and compounds. Using a one-compartment in vitro infection model, the PK-PD of tazobactam administered in combination with cefepime was characterized, and a translational relationship across ESBL-producing Enterobacteriaceae was developed. Four clinical isolates, two Escherichia coli and two Klebsiella pneumoniae isolates, known to produce CTX-M-15 β-lactamase enzymes and displaying cefepime MIC values of 2 to 4 mg/liter in the presence of 4 mg/liter tazobactam, were evaluated. Tazobactam threshold concentrations from 0.0625× to 1× the tazobactam-potentiated cefepime MIC value were considered. The threshold that best described the relationship between tazobactam %T>threshold and change in log10 CFU/ml from the baseline at 24 h was the product of 0.125 and the cefepime-tazobactam MIC (R2 = 0.813). The magnitudes of %T>threshold associated with net bacterial stasis and a 1-log10 CFU/ml reduction from baseline at 24 h were 21.9% and 52.8%, respectively. These data will be useful in supporting the identification of tazobactam dosing regimens in combination with cefepime for evaluation in future clinical studies.

Keywords: cefepime; pharmacokinetics-pharmacodynamics; tazobactam.

MeSH terms

  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / pharmacology*
  • Bacterial Proteins / metabolism
  • Cefepime
  • Cephalosporins / pharmacokinetics
  • Cephalosporins / pharmacology*
  • Drug Resistance, Multiple, Bacterial / physiology
  • Drug Therapy, Combination
  • Escherichia coli / drug effects*
  • Escherichia coli / isolation & purification
  • Escherichia coli Proteins / metabolism
  • Klebsiella pneumoniae / drug effects*
  • Klebsiella pneumoniae / isolation & purification
  • Lipoproteins / metabolism
  • Membrane Transport Proteins / metabolism
  • Microbial Sensitivity Tests
  • Models, Biological
  • Penicillanic Acid / analogs & derivatives*
  • Penicillanic Acid / pharmacokinetics
  • Penicillanic Acid / pharmacology
  • Tazobactam
  • beta-Lactamase Inhibitors / pharmacokinetics
  • beta-Lactamase Inhibitors / pharmacology*
  • beta-Lactamases / metabolism

Substances

  • AcrA protein, E coli
  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Cephalosporins
  • Escherichia coli Proteins
  • Lipoproteins
  • Membrane Transport Proteins
  • beta-Lactamase Inhibitors
  • Cefepime
  • Penicillanic Acid
  • beta-lactamase CTX-M-15
  • AmpC beta-lactamases
  • beta-Lactamases
  • Tazobactam